Ayala Pharmaceuticals (NASDAQ:ADXS) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a report released on Saturday. The firm set a “sell” rating on the stock.

Ayala Pharmaceuticals Trading Up 250.3 %

Shares of Ayala Pharmaceuticals stock opened at $0.11 on Friday. The firm has a market capitalization of $4.48 million, a PE ratio of -0.01 and a beta of 1.63. The firm’s 50 day moving average is $0.03 and its 200 day moving average is $0.03. Ayala Pharmaceuticals has a 1 year low of $0.00 and a 1 year high of $0.97.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.